Gastric motility refers to the contractions of the stomach that help in digestion. Gastric motility disorders include conditions that slow down or speed up the movement of food through the stomach. Common gastric motility disorders include gastroparesis and dumping syndrome. Gastric motility disorder drugs help modulate gastric emptying and treat symptoms associated with gastric motility dysfunction. Some of the commonly prescribed drugs are prokinetics, antidopaminergics, antiemetics, anticholinergics, and other gastrointestinal products.
The Global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.
The global gastric motility disorder drug market is driven by the growing prevalence of diabetes, increasing demand for novel drug delivery systems, and advancements in drug formulations. Gastric motility disorders are quite common in patients with diabetes due to diabetic neuropathy. Moreover, several pharmaceutical companies are focusing on the development of novel drug formulations such as extended-release formulations and drug combinations to improve treatment outcomes.
Key Takeaways
Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
The market is expected to witness significant growth opportunities due to the rising incidence of diabetes and increasing adoption of gastric pacemakers. Gastric pacemakers help modulate gastric contractions and emptying through electrical stimulation and are used to treat gastroparesis and other gastric motility issues.
Several new drug formulations and drug delivery systems such as orally disintegrating tablets, subcutaneous injections, and continuous intrajejunal infusions are being evaluated which can significantly improve the treatment experience of patients. Drugs with novel mechanisms of action targeting neuronal pathways and interstitial cells of Cajal are also being explored.
Market Drivers
Growing prevalence of diabetes: Diabetes is a leading risk factor for gastric motility disorders and has become quite common globally. It is estimated that by 2045, around 700 million people worldwide will have diabetes. This will significantly drive the demand for gastric motility drugs.
Rising awareness and improved diagnosis: Initiation of awareness programs and availability of advanced diagnostic techniques are enabling quicker diagnosis of gastric motility issues. This is encouraging more patients to seek medical help.
Potential of gastric pacemakers: Gastric pacemakers have shown promise in improving symptoms in drug-refractory patients and their adoption is increasing gradually. This will further fuel the gastric motility drugs market growth over the coming years.
Current challenges in Gastric Motility Disorder Drug market:
Some of the major challenges faced by the gastric motility disorder drug market are high cost of treatment, patent expiries of blockbuster drugs, failure of drug candidates, and stringent regulatory guidelines. Gastric motility disorder treatments are often long-term and involve high costs which many patients cannot afford. Further, patent expiries of major drugs is leading to decline in market revenues of companies. Around 15 drugs failed in clinical trials between 2014-2019 due to safety and efficacy issues. Additionally, regulatory authorities have implemented strict rules for approval of new drug candidates which increases clinical trials cost and time.
SWOT Analysis:
Strengths: Growing prevalence of gastric motility disorders like gastroparesis and increasing awareness. Presence of major pharmaceutical companies with strong R&D pipelines.
Weaknesses: High costs of drug development and treatment. Risk of drug failure and side effects. Dependence on few blockbuster drugs.
Opportunities: Emerging drug delivery technologies and alternative treatment options. Untapped growth potential in developing countries.
Threats: Patent expiries of major drugs. Stringent regulations for approval. Increased generics competition.
Geographically, North America is currently dominating the gastric motility disorder drug market and holds around 45% of global market share. This is majorly due to growing disease prevalence, high healthcare spending, and availability of advanced treatment facilities in the US and Canada. However, Asia Pacific region is expected to grow at the fastest pace during the forecast period owing to large patient pool, rising healthcare awareness, and increasing GDP spend on healthcare. China and India are emerging as highly lucrative markets in Asia.
In terms of value, developed markets of Western Europe and North America currently account for over 65% share of global gastric motility disorder drug market. This is because of well-established pharmaceutical companies, high patient uptake for novel therapies, and favorable reimbursement scenario. However, developing regions like Asia Pacific and Latin America are projected to offer highest growth opportunities during next few years primarily due to expanding healthcare infrastructure and significant disease burden.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
